Galera Therapeutics is a clinical-stage biopharmaceutical company focused on developing tilarginine (L-NMMA), a pan-inhibitor of nitric oxide synthase (NOS), as a treatment for metaplastic breast cancer (MpBC) and triple-negative breast cancer (TNBC). Galera pivoted to this focus in late 2024 via the acquisition of Nova Pharmaceuticals, which held a license from Houston Methodist — the institution that discovered the RPL39/NOS pathway driving tumor growth in MpBC. In October 2025, Galera sold its legacy drug assets to Biossil for $3.5M upfront plus up to $105M in contingent milestones, leaving tilarginine as its sole program. The scientific rationale centers on the finding that MpBC tumors overexpress RPL39, which drives nitric oxide production and promotes metastasis; inhibiting NOS with tilarginine has shown a 45.8% overall response rate in an early Phase 1/2 TNBC/MpBC trial with no severe attributed toxicities. Galera's lead program is an investigator-sponsored Phase 1/2 trial funded by an NIH grant to Houston Methodist, which also covers drug supply, meaningfully reducing Galera's cash burn. The trial has advanced to Phase 2a and expanded to MD Anderson and the NIH Clinical Center. Galera has no revenue, just 3 employees, and trades on the OTCQB market. Its path to value realization would most likely come through a licensing deal or acquisition rather than independent commercialization.